100 studies found for:    ct-p13
Show Display Options
Rank Status Study
1 Recruiting Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: CT-P13;   Biological: Remicade
2 Completed An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
Condition: Rheumatoid Arthritis
Intervention: Biological: Infliximab
3 Completed An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1
Condition: Ankylosing Spondylitis
Intervention: Biological: Infliximab
4 Completed Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
Condition: Rheumatoid Arthritis
Intervention: Drug: Infliximab
5 Completed Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
Condition: Ankylosing Spondylitis
Intervention: Drug: Infliximab
6 Not yet recruiting The NOR-SWITCH Study
Conditions: Rheumatoid Arthritis;   Spondyloarthritis;   Psoriatic Arthritis;   Ulcerative Colitis;   Crohn's Disease;   Psoriasis Chronic
Interventions: Drug: Innovator infliximab;   Drug: Biosimilar infliximab
7 Completed Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: aldesleukin;   Biological: filgrastim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: therapeutic hydrocortisone;   Radiation: radiation therapy
8 Active, not recruiting High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET);   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Primary Systemic Amyloidosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Neuroblastoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Regional Neuroblastoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: etoposide;   Drug: cyclophosphamide;   Drug: carmustine;   Drug: melphalan;   Drug: busulfan;   Drug: carboplatin;   Drug: thiotepa;   Radiation: total-body irradiation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
9 Completed Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Conditions: Leukemia;   Lung Cancer;   Malignant Mesothelioma;   Myelodysplastic Syndromes;   Primary Peritoneal Cavity Cancer
Interventions: Biological: WT-1 analog peptide vaccine;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunoenzyme technique
10 Completed Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab;   Drug: arsenic trioxide;   Drug: azacitidine;   Drug: busulfan;   Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Drug: gemtuzumab ozogamicin;   Drug: melphalan;   Drug: tipifarnib;   Genetic: DNA methylation analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
11 Active, not recruiting Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: gemtuzumab ozogamicin
12 Recruiting Empirical Versus Preemptive Antifungal Therapy
Conditions: Fungal Infection;   Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: caspofungin acetate
13 Completed
Has Results
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
Condition: Pneumococcal Conjugate Vaccine
Intervention: Biological: 13-valent Pneumococcal Conjugate Vaccine
14 Recruiting T Cell Effector and Regulatory Mechanisms in Asthma
Conditions: Asthma;   Allergies
Interventions: Biological: Allergen Challenge;   Procedure: PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
15 Recruiting Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Condition: Squamous Cell Carcinoma of the Oropharynx, Larynx, or Hypopharynx
Interventions: Drug: Cisplatin;   Radiation: IMRT;   Drug: Docetaxel;   Drug: Cetuximab
16 Completed
Has Results
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
Condition: Cystic Fibrosis
Interventions: Drug: tobramycin / Bramitob;   Drug: tobramycin / TOBI
17 Recruiting PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Condition: Esophageal Cancer
Intervention: Device: MRI and PET-CT
18 Recruiting Cardiac GSI Feasibility Study
Condition: High Risk of Significant Coronary Artery Disease
Intervention: Device: Cardiac GSI
19 Recruiting AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure
Conditions: Heart Failure Congestive;   Ischemic Cardiomyopathy;   Non-ischemic Cardiomyopathy
Interventions: Genetic: MYDICAR-single intracoronary infusion;   Genetic: Placebo; single intracoronary infusion
20 Recruiting Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies
Condition: Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients
Intervention: Other: [18F] - Fludarabine PET/CT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years